Director share purchases

August 14, 2023

LungLife AI, Inc.
(the “Company” or “LungLife”) 

Director share purchases

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors.

On 14 August 2023, Paul Pagano, Chief Executive Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, Paul Pagano now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

In addition, on 14 August 2023, David Anderson, Chief Financial Officer, purchased 7,123 Common Shares at a price of 69.84 pence per share. Following this purchase, David Anderson now holds 12,123 Common Shares, representing approximately 0.047% of the outstanding share capital of the Company.

Click HERE for the full announcement.

Recent News

Clinical validation study update
Director share purchases
Half-year Report

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down